Hopkinton-based Isto Biologics, a biologic and cellular therapy company in the orthopedic space, has acquired Los Angeles-based TheraCell, Inc.
The acquisition will strengthen Isto’s solutions for surgical and clinical care procedures within spine, orthopedics, and sports medicine, according to a press release from Isto.
“TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade,” Isto CEO Don Brown said in the release.
Isto Biologics products include a platelet separator and bone-growth products. Theracell’s TheraFuze DBF technology will become part of Isto Biologics’ Influx bone-growth line, according to the release.
Isto Biologics is a portfolio company of St. Louis-based Thompson Street Capital Partners.
Financial details of the acquisition were not released.
